Sucralose affects response to oral glucose load in obese

July 2, 2013
Sucralose affects response to oral glucose load in obese
For obese adults who do not use non-nutritive sweetener, sucralose affects the glycemic and insulin responses to an oral glucose load, according to a study published online April 30 in Diabetes Care.

(HealthDay)—For obese adults who do not use non-nutritive sweetener (NNS), sucralose affects the glycemic and insulin responses to an oral glucose load, according to a study published online April 30 in Diabetes Care.

M. Yanina Pepino, Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues examined the acute effects of sucralose ingestion on the metabolic response to an oral glucose load in 17 obese individuals who did not use NNS and were insulin sensitive. In a randomized crossover design study, participants underwent a five-hour modified on two occasions 10 minutes after consuming sucralose or water.

The researchers found that sucralose ingestion caused significantly greater incremental increases in peak concentrations and insulin area under the curve, as well as a greater peak rate, and caused significant decreases in insulin clearance and insulin sensitivity, compared with the control condition. For active glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, glucagon incremental area under the curve, or indices of sensitivity to the ?-cell response to glucose, there were no significant differences between the conditions.

"In conclusion, the results from our study demonstrate that sucralose affects the glycemic and hormonal responses to an oral glucose load in obese people who do not normally consume NNS," the authors write. "These findings support the notion that sucralose is not metabolically inert but has physiologic effects."

Tate & Lyle provided sucralose for the study.

Explore further: Insulin LY2605541 tops glargine for glycemic control in T1DM

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Bile acid sequestrant reduces glucose concentration in T2DM

January 30, 2013

(HealthDay)—For patients with type 2 diabetes taking metformin monotherapy, the bile acid sequestrant colesevelam reduces fasting and postprandial glucose concentrations without any effects on insulin concentration, secretion, ...

Recommended for you

Do germs cause type 1 diabetes?

May 16, 2016

Germs could play a role in the development of type 1 diabetes by triggering the body's immune system to destroy the cells that produce insulin, new research suggests.

Melatonin signaling is a risk factor for type 2 diabetes

May 12, 2016

A sleeping pancreas releases less insulin, but how much insulin drops each night may differ from person to person, suggests a study published May 12, 2016 in Cell Metabolism. Up to 30 percent of the population may be predisposed ...

New gene for familial high cholesterol

May 12, 2016

New research from Denmark reveals the gene that explains one quarter of all familial hypercholesterolemia with very high blood cholesterol. Familial hypercholesterolemia is the most common genetic disorder leading to premature ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.